SARS CoV 2 News and Research

RSS

How COVID-19 impacted sleep and mental health among university students

In a recent study published in the journal PLoS ONE, researchers evaluated the effects of coronavirus disease 2019 (COVID-19) on the sleep quality and mental health (MH) of university-attending undergraduate students.

30 Oct 2022

SARS-CoV-2 infection can affect menstruation

Researchers assess the association between SARS-CoV-2 infection and menstrual irregularities.

30 Oct 2022

An estimated 15% of U.S. adults infected with SARS-CoV-2 have long-COVID

In a recent study published in the journal JAMA Network Open, researchers in the United States estimated the sociodemographic factors associated with and prevalence of post-acute coronavirus disease 2019 (COVID-19) symptom sequelae (PASC) or long COVID (LCOVID).

30 Oct 2022

An evaluation of the response to nationwide COVID-19 testing in England

Researchers in the Netherlands and the United Kingdom formulated recommendations for future pandemics using lessons learned from the testing programs implemented in the United Kingdom (UK) during the ongoing coronavirus disease 2019 (COVID-19) pandemic.

30 Oct 2022

Favorable outcomes of infants born after maternal COVID-19 during pregnancy

Researchers assess the outcomes of children born to mothers infected during pregnancy with SARS-CoV-2.

30 Oct 2022

Estimating the risk of airborne SARS-CoV-2 transmission in a train carriage

Researchers evaluate the risk of airborne transmission of SARS-CoV-2 in a mechanically ventilated inter-city train carriage.

30 Oct 2022

New insights on antibody response against SARS-CoV-2 Omiron sublineages

Knowing how well vaccination against one SARS-CoV-2 strain (with or without previous infection) counteracts infection with a different strain is a critical research question.

28 Oct 2022

First anti-SARS Cov2 monoclonal antibody candidate of SpikImm demonstrates excellent tolerance

SPK001, the first anti-SARS Cov2 monoclonal antibody candidate of SpikImm, a French biotechnology company founded by Truffle Capital, originally discovered by the Institut Pasteur's Human Immunology Laboratory, directed by Dr. Hugo Mouquet (Inserm Joint Research Unit), has been tested on three initial cohorts of healthy volunteers, and has demonstrated excellent tolerance, in the context of the Phase 1 clinical study, recently labeled as a "national priority" by CAPNET (National Steering Committee for Therapeutic Trials and other Research on Covid-19).

28 Oct 2022

The impact of seasonal coronavirus immunity on susceptibility to SARS-CoV-2 infection and COVID-19 vaccination

Researchers investigated whether immunity against seasonal human coronavirus spike proteins of HKU1, OC43, NL63, or 229E could protect against SARS-CoV-2 in vitro.

28 Oct 2022

Booster vaccination offered additional protection to residents and staff of California state prisons against SARS-CoV-2 Omicron

Researchers evaluated to what extent prior infection and vaccination protected the residents and staff of the United States California state prison system from breakthrough infection by SARS-CoV-2 Omicron sub-variant B.1.1.529.

28 Oct 2022

Study refutes the nicotinic hypothesis of SARS-CoV-2 infection mechanism

A new study confirmed that the SARS-CoV-2 spike protein does not bind to human AChR’s orthosteric sites, nor does it compete with ACh, choline, or nicotine.

28 Oct 2022

The epigenetic alterations of monocytes in severe COVID-19

Researchers performed DNA methylation analysis on monocytes in the peripheral blood samples obtained from severe COVID-19 patients.

28 Oct 2022

Association of COVID-19 severity with nasopharyngeal fungal colonization and interleukin-17 induction

Researchers evaluated the concurrent colonization of fungi in the nasopharynx of severe COVID-19 patients.

28 Oct 2022

Low-density granulocytes are phenotypically altered in people with long-COVID

In a recent study posted to the bioRxiv* preprint server, researchers characterized low-density granulocyte (LDG) neutrophil (NP) proportion among individuals up to 14 months post-SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2) infection.

28 Oct 2022

Scientists computationally restore the potency of an antibody against SARS-CoV-2 Omicron subvariants

A team of researchers from the United States computationally modified the COV2-2130 monoclonal antibody to restore its neutralizing ability against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Omicron subvariants, while retaining efficacy against the Delta and wild-type strains.

27 Oct 2022

Combination of multi-specificity and antibody avidity enhances protection against SARS-CoV-2

In a recent study posted to the bioRxiv* preprint server, an international team of researchers leveraged the human light chain apoferritin protomer-derived MULTI-specific, multi-Affinity antibody (Multabody, MB) platform for the generation of broad and potent SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2)-neutralizing antibodies (Abs).

27 Oct 2022

Ancient viral DNA in human genomes protects cells against present-day viruses

Viral DNA in human genomes, embedded there from ancient infections, serve as antivirals that protect human cells against certain present-day viruses, according to new research.

27 Oct 2022

Updapted BA.4/5 COVID vaccines boost protection but might not surpass original formula

In a recent study posted to the bioRxiv* preprint server, researchers at Beth Israel Deaconess Medical Center assessed the immunogenicity associated with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) BA.5 bivalent messenger ribonucleic acid (mRNA) vaccine boosters.

27 Oct 2022

Immune checkpoint therapy may be beneficial in certain cases of severe COVID-19

An article published in Science Advances suggests that a type of cancer treatment known as immune checkpoint blockade may be beneficial in certain cases of severe COVID-19.

27 Oct 2022

Long COVID, a new clinical entity constantly evolving

Researchers discuss the epidemiology, diagnosis, pathogenesis, and treatment of long COVID.

27 Oct 2022

SARS CoV 2 News and Research

How COVID-19 impacted sleep and mental health among university students

SARS-CoV-2 infection can affect menstruation

An estimated 15% of U.S. adults infected with SARS-CoV-2 have long-COVID

An evaluation of the response to nationwide COVID-19 testing in England

Favorable outcomes of infants born after maternal COVID-19 during pregnancy

Estimating the risk of airborne SARS-CoV-2 transmission in a train carriage

New insights on antibody response against SARS-CoV-2 Omiron sublineages

First anti-SARS Cov2 monoclonal antibody candidate of SpikImm demonstrates excellent tolerance

The impact of seasonal coronavirus immunity on susceptibility to SARS-CoV-2 infection and COVID-19 vaccination

Booster vaccination offered additional protection to residents and staff of California state prisons against SARS-CoV-2 Omicron

Study refutes the nicotinic hypothesis of SARS-CoV-2 infection mechanism

The epigenetic alterations of monocytes in severe COVID-19

Association of COVID-19 severity with nasopharyngeal fungal colonization and interleukin-17 induction

Low-density granulocytes are phenotypically altered in people with long-COVID

Scientists computationally restore the potency of an antibody against SARS-CoV-2 Omicron subvariants

Combination of multi-specificity and antibody avidity enhances protection against SARS-CoV-2

Ancient viral DNA in human genomes protects cells against present-day viruses

Updapted BA.4/5 COVID vaccines boost protection but might not surpass original formula

Immune checkpoint therapy may be beneficial in certain cases of severe COVID-19

Long COVID, a new clinical entity constantly evolving

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News